retatrutide trial phase Shows 28% Weight Loss in 80 Weeks Phase III retatrutide study demonstrates

\Energy Expenditure: Promotes thermogenesis and fatty acid oxidation through glucagon receptor activity

Curr Enzyme Inh 7:206217 Mojsov S (1992) Structural requirements for biological activity of glucagon-like peptide-I

Tesfaye, H

GLP-1 Weight loss tracker: 12-Week Journal tracking each Day to Support Your Journey

OCA downregulates hepatic glucose and lipid metabolism by downregulating SREPB-1c and reducing endogenous bile acid production, via upregulation of FGF19 which then inhibits CYP7A1, the rate-limiting enzyme for the conversion of cholesterol to bile acids.81In addition to these primary metabolic effects, OCA may also decrease portal pressure by increasing iNOS and displaying a wider range of anti-inflammatory and antifibrotic activity.[82], [83] The FXR Ligand Obeticholic Acid in NASH Treatment (FLINT) trial was a randomised, placebo-controlled, phase IIb trial to evaluate the safety and efficacy of OCA in NASH